Phase 1 subject disposition and basic characteristics
| Attribute . | AB002 . | Placebo . | Total [%] . | |||
|---|---|---|---|---|---|---|
| 0.5 µg/kg . | 1.0 µg/kg . | 2.0 µg/kg . | 4.0 µg/kg . | |||
| Subjects included | 4 | 4 | 4 | 4 | 5 | 21 [100] |
| Subjects withdrawn | 0 | 0 | 0 | 0 | 0 | 0 [0] |
| Male subjects | 1 | 2 | 2 | 1 | 1 | 7 [33] |
| Female subjects | 3 | 2 | 2 | 3 | 4 | 14 [67] |
| Age, mean (SD), y | 44.0 (5.4) | 37.3 (10.3) | 33.8 (10.0) | 36.0 (12.0) | 43.0 (9.4) | 39.0 [9.6] |
| Weight, mean (SD), kg | 70.9 (14.1) | 77.4 (7.3) | 73.9 (7.8) | 69.3 (11.8) | 73.7 (12.8) | 73.0 [10.4] |
| BMI, mean (SD), kg/m2 | 26.6 (2.5) | 25.8 (2.2) | 27.2 (1.3) | 26.2 (2.6) | 25.3 (1.8) | 26.2 [2.0] |
| Attribute . | AB002 . | Placebo . | Total [%] . | |||
|---|---|---|---|---|---|---|
| 0.5 µg/kg . | 1.0 µg/kg . | 2.0 µg/kg . | 4.0 µg/kg . | |||
| Subjects included | 4 | 4 | 4 | 4 | 5 | 21 [100] |
| Subjects withdrawn | 0 | 0 | 0 | 0 | 0 | 0 [0] |
| Male subjects | 1 | 2 | 2 | 1 | 1 | 7 [33] |
| Female subjects | 3 | 2 | 2 | 3 | 4 | 14 [67] |
| Age, mean (SD), y | 44.0 (5.4) | 37.3 (10.3) | 33.8 (10.0) | 36.0 (12.0) | 43.0 (9.4) | 39.0 [9.6] |
| Weight, mean (SD), kg | 70.9 (14.1) | 77.4 (7.3) | 73.9 (7.8) | 69.3 (11.8) | 73.7 (12.8) | 73.0 [10.4] |
| BMI, mean (SD), kg/m2 | 26.6 (2.5) | 25.8 (2.2) | 27.2 (1.3) | 26.2 (2.6) | 25.3 (1.8) | 26.2 [2.0] |
BMI, body mass index; SD, standard deviation.